Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient

Hirotsu, Kelsey E.; Hua, Vivian; Tran, Anhthy T; Morris, Laura; Reddy, Sunil; Kwong, Bernice Y.; Zaba, Lisa C.

doi:10.1016/j.jdcr.2021.05.005

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 , 2 Our case adds to the previous case reports on T-VEC in MCC ( Table I ) and highlights its potential as an alternative immunotherapy option for patients who may have anti-PD-(L)-1 refractory disease or may have serious contraindications to receiving systemic immunotherapy. 3 , 4 , 5 , 6 , 7 , 8 , 9 Our case also suggests that T-VEC can lead to rapid regression of injected MCC tumors and has potential to provide systemic control beyond just the injected tumors. It can also be administered concurrently with radiation therapy for a possible synergistic effect.…”

mentioning

confidence: 71%

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec

McClure¹,

Doolittle‐Amieva²,

Parvathaneni³

et al. 2023

JAAD Case Reports

View full text Add to dashboard Cite

mentioning

confidence: 71%

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec

McClure¹,

Doolittle‐Amieva²,

Parvathaneni³

et al. 2023

JAAD Case Reports

View full text Add to dashboard Cite

“…165 Isolated case reports have described successful administration of T-VEC in carefully selected patients with a history of solid organ transplant with close monitoring and multidisciplinary consultation. [166][167][168] However, because T-VEC is a live virus that may cause life-threatening disseminated herpes infection, it is not routinely recommended for immunosuppressed or pregnant patients. 169 Additionally, OPTiM excluded patients with a serum LDH >1.5 times the upper limit of normal, >3 visceral metastases (except lung or nodal organ metastases), visceral metastases >3 cm, unstable liver metastases, bone metastases, and active cerebral metastases, therefore careful consideration must be given when administering T-VEC as there were no US FDA approvals for use of this agent in combination with systemic treatment at the time of guideline publication.…”

Section: Indications For T-vecmentioning

confidence: 99%

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Pavlick,

Ariyan,

Buchbinder

et al. 2023

J Immunother Cancer

View full text Add to dashboard Cite

Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, more recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long-term follow-up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence-free survival, and neoadjuvant strategies are an active area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma and bispecific T-cell engager therapy for HLA-A*02:01 genotype-positive uveal melanoma, are also available to patients. Despite the remarkable efficacy of these regimens for many patients with cutaneous melanoma, traditional immunotherapy biomarkers (ie, programmed death-ligand 1 expression, tumor mutational burden, T-cell infiltrate and/or microsatellite stability) have failed to reliably predict response. Furthermore, ICIs are associated with unique toxicity profiles, particularly for the highly active combination of anti-PD-1 plus anti-CTLA-4 agents. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of melanoma, including rare subtypes of the disease (eg, uveal, mucosal), with the goal of improving patient care by providing guidance to the oncology community. Drawing from published data and clinical experience, the Expert Panel developed evidence- and consensus-based recommendations for healthcare professionals using immunotherapy to treat melanoma, with topics including therapy selection in the advanced and perioperative settings, intratumoral immunotherapy, when to use immunotherapy for patients withBRAFV600-mutated disease, management of patients with brain metastases, evaluation of treatment response, special patient populations, patient education, quality of life, and survivorship, among others.

show abstract

An update on Merkel cell carcinoma

Sergi

Lauricella

Porta

et al. 2023

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient

Cited by 4 publications

References 8 publications

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

An update on Merkel cell carcinoma

Contact Info

Product

Resources

About